Anna Oleksiak: Is Thrombocytopenia in Critical Cardiac Care HIT?
Anna Oleksiak, Cardiologist at National Institute of Cardiology Stefan Cardinal Wyszyński – National Research Institute, shared a post on LinkedIn:
”At ICCU often patient’s platelets drop…
The clinical question – is this HIT, drugs interaction, mechanical injury, MCS, clotting, sepsis or something else?
But there is not much time for the right decisions.
Here are some pages from Association for Acute CardioVascular Care – ACVC Clinical Decision Making Toolkit, chapter about anticoagulation in critically ill, written by me and Christophe Vandenbriele last year.
Some hot points about heparin-induced thrombocytopenia:
- T Score is the most widely used and well-validated risk-prediction score and has excellent negative predictive value.
- An important problem in diagnosing thrombocytopenia is the exclusion of pseudothrombocytopenia, resulting from platelet agglutination in blood collected in an EDTA.
- HIT should be suspected in patients receiving heparin if, for an unknown reason:
1) the platelet count has decreased by ≥50% from the baseline (even if it is 150,000/µL);
2) ≥5 days have passed since the start of heparin administration;
3) a thromboembolic event has occurred;
4) no other causes of thrombocytopenia are identified.
- UFH conveys a HIT risk 10 times greater than that of LMWH.
- Frequently, post-surgical patients exhibit a unique bimodal pattern of platelet decline.
- Although thrombocytopenia is usually a serious problem in the context of bleeding, the occurrence of HIT type II is associated with a 20-40 fold increase in the risk of venous or arterial thrombosis, with an incidence of thrombosis ranging from 50% to 89% in untreated patients.
- The most common cause of death in patients with HIT is pulmonary embolism, less frequently stroke.
- Typically, the heparin-dependent antibodies fall to undetectable levels after 50 to 85 days.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines